Ben Kamens is the founder and CEO of Spring Discovery, a company devoted to accelerating therapies for aging and its diseases. Prior to that, Ben was the first engineer for Khan Academy, which provides free online education to millions of users around the world. Today Ben joins host Chris Patil to discuss Spring Discovery’s mission to increase healthy lifespan and dramatically reduce disease, his experience with Khan Academy and how it connected to his work in biotechnology, and overcoming challenges in the field of aging. 

Ben tells Chris about his pragmatic approach to building a company, how Spring Discovery plans to accelerate drug discovery and clinical development, and their collegial relationship with BioAge and other companies in the longevity biotech sector. Ben chats about Spring Discovery’s recent Series B funding, then offers a sneak peek into their therapeutic pipeline, and details his experience running a nonprofit clinical trial for a generic drug to fight against COVID, including what this taught him about testing drugs for age-related indications. Finally, Ben shares his favorite aspect of longevity science that his company is not currently working on, and where he sees the field of aging moving toward over the next five to ten years.

To learn more about Ben and Spring Discovery’s work to accelerate drug discovery with machine learning, visit springdiscovery.com.

Episode Highlights:

• Ben Kamens is the founder and CEO of Spring Discovery; he was also the first engineer for Khan Academy
• Introduction to Spring Discovery and how recent Series B funding will help the company advance its work to increase healthy lifespan and dramatically reduce disease
• His initial skepticism and passion for fighting disease 
• Overcoming obstacles in the field of aging
• Building value and resources as a company over time
• Accelerating drug discovery and clinical development
• Machine learning approach
• Spring Discovery’s therapeutic pipeline
• Ben’s involvement running a nonprofit clinical trial for a generic drug against COVID, and what this taught him about testing drugs for age-related indications
• You can read Ben’s article “COVID-19 is the latest disease to point at our need to treat immune aging” here
• Favorite aspect of longevity science that his company is not currently working on

Quotes:

“I couldn't think of a more important mission to try to enable than battling diseases of aging. And our mission is to give the best technology possible to these people who are doing what we think is the most important work possible.”

“I came to this field as an outsider and somebody who's really a team builder, and interested in deploying the intersection of scientists and technology to try to fight disease.”

“I am an extremely pragmatic person, especially when it comes to company building and entrepreneurialism.”

“When you mention aging, you're immediately talking about this extremely broad array of biological phenomena, some of which are going to be relevant clinically, some of which are not.”

“This presented a real opportunity to build the best company in the world at measuring the many changes that occur in us as we age.”

“We've essentially taken an engineering throughput mindset to disentangling the many dimensions of age-related changes that accrue in our cells and tissues over time, and built a company around getting really, really good at that, and then using that to much more quickly search for therapies.”

“You can think of it as a big engine that takes in a whole bunch of primary human samples, spits out this very multidimensional, complete view of cellular function, but does it in a big single screen that's combining tons of phenotypic imaging data with proteomics data, and then uses a set of models we built up to identify different cellular functions that are being identified in that raw data.”

“I do not view that as competition whatsoever. I have nothing but respect for BIOAGE.”

“We can cause all sorts of problems for ourselves. I don't really know what a competitor would do that would really dramatically change our trajectory.”

“Our current focus is in the world of immune aging, and specifically how immune aging applies to both the pulmonary and skin therapeutic areas.”

“We were following our standard path. And then, as you know, the more data that came out, the more it became very obvious that, more so than any other comorbidity, one's age defined one’s outcome with COVID. And it was almost looking like people who are much older who get COVID have an entirely different disease than people who are much younger.”

“For most diseases, they are way worse for you if you're older, and so where is all the therapeutic effort that is focused on that huge fact in COVID?”

“I am very uniquely proud that we found a way to do this.”

“For me, this was just validation that there are ways to run pragmatic, cost effective, timely clinical trials for diseases that are exacerbated by the biology of aging.”

Links:

Email questions, comments and feedback to [email protected]

Translating Aging on Twitter: @bioagepodcast

BIOAGE Labs Website BIOAGELabs.com

BIOAGE Labs Twitter @bioagelabs

BIOAGE Labs LinkedIn

Spring Discovery Website springdiscovery.com